COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Amnioband and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02609594
Recruitment Status : Recruiting
First Posted : November 20, 2015
Last Update Posted : September 7, 2018
Musculoskeletal Transplant Foundation
Information provided by (Responsible Party):
Thomas Serena, SerenaGroup, Inc.

Brief Summary:

Lower extremity ulcers pose significant clinical, humanistic and economic burdens on society. Millions of Americans are afflicted with painful, open, draining sores on their lower extremities. These sores are referred to as venous leg ulcerations (VLUs).1-5 Under the best of circumstances these ulcers require weeks or months to heal. Not uncommonly wound care specialists see patients who have suffered for years or faced amputation of the limb as their only option to alleviate the pain.

Standard of care will result in healing in 50% of venous leg ulcers in 12 weeks. However, roughly half of patients suffering from venous ulcers will require advanced therapy. Human amniotic membrane replaces the damaged extracellular matrix characteristic of chronic ulcers. In addition, it contains cytokines that may accelerate healing. In clinical practice and recent studies, Dehydrated Human Amniotic Membrane has appeared to be as effective as bioengineered skin products. This RCT is designed to evaluate Amnioband Dehydrated Human Amniotic Membrane in venous leg ulcers.

Condition or disease Intervention/treatment Phase
Venous Leg Ulcers Other: Weekly application of Amnioband Other: Biweekly application of Amnioband Other: Standard of Care Not Applicable

Detailed Description:

This study is a multi-center, randomized, trial designed to evaluate the safety and effectiveness of Amnioband Dehydrated Human Amniotic Membrane plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.

The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The choice of compression will be at the discretion of the principle investigator.

The Screening Phase (1-14 days) consists of a series of screening assessments designed to determine eligibility followed by, for those who meet the eligibility criteria (described in more detail below), At or up to 14 days before the first Screening Period Visit (S1), written informed consent from the subject will be obtained by the Investigator or suitably qualified designee before the performance of any other protocol-specific procedure.

Subjects who have not been treated with compression therapy for the target ulcer must receive a minimum of 14 days of compression prior to enrollment.

At the first Screening Period Visit (S1), the Investigator will select the study (target) ulcer. Each subject will have only one VLU selected as the study (target) ulcer. In the situation where a subject has more than one VLU at the S1 visit, the Investigator will select the largest VLU that meets the eligibility criteria of the protocol as the study (target) ulcer.

The Screening Period is designed to determine whether subjects are eligible to proceed to the Treatment Period of the study.

The Treatment Phase (12 Weeks) begins with a series of assessments designed to confirm the subjects' continued eligibility. Subjects who continue to meet eligibility criteria will be randomized to one of three groups: (1) standard of care: multi-layer compression (2) weekly application of Amnioband Dehydrated Human Amniotic Membrane (3) biweekly applications of Amnioband Dehydrated Human Amniotic Membrane.

During the Treatment Phase, subjects will be evaluated on a weekly basis. Efficacy evaluations each week will include Investigator assessment of ulcer healing and measurements of ulcer size using a digital camera device. Safety evaluations during the Treatment Phase will consist of adverse event assessments at each visit.

Subjects in any of the three groups whose ulcers do not achieve closure at 12 weeks will be deemed treatment failures. Subjects in the control arm may cross over to the Amnioband arm if they fail to achieve closure although these subjects will not be included in the analysis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Amnioband Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers
Study Start Date : November 2015
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Standard of Care
Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
Other: Standard of Care
Standard of care for this study is weekly multi-layer compression bandaging.

Experimental: Weekly application of Amnioband
Weekly application of Amnioband plus standard of care.
Other: Weekly application of Amnioband
Weekly application of Amnioband.

Other: Standard of Care
Standard of care for this study is weekly multi-layer compression bandaging.

Experimental: Biweekly application of Amnioband
Biweekly application of Amnioband plus standard of care.
Other: Biweekly application of Amnioband
Biweekly application (every two weeks) of Amnioband.

Other: Standard of Care
Standard of care for this study is weekly multi-layer compression bandaging.

Primary Outcome Measures :
  1. Time to complete ulcer closure [ Time Frame: 12 weeks ]
    Ulcer closure is based on wound area measurement and absence of wound exudate.

Secondary Outcome Measures :
  1. Proportion of ulcers achieving 40% ulcer closure [ Time Frame: 4 weeks ]
    This is measured by wound area.

  2. Percentage of ulcers achieving complete closure [ Time Frame: 12 weeks ]
    This is measured by wound area and absence of wound exudate.

  3. Incidence of adverse events [ Time Frame: 12 weeks ]
  4. Cost effectiveness [ Time Frame: 12 weeks ]
    The per unit cost of providing wound care is known. The use of amniotic membrane to standard of care will be compared in terms of the cost of achieving healing.

  5. Reduction in pain between treatment groups [ Time Frame: 12 weeks ]
    Pain is measured by subject report on a scale of 0 to 10.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. At least 18 years old.
  2. Ankle Brachial Pressure Index (ABI) > 0.75 OR SPP > 30 mmHg OR TCOM > 30 mmHg.*
  3. Presence of a venous leg ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone.
  4. The largest ulcer will be designated the index ulcer and the only one included in the study. If other ulcerations are present on the same leg they have to be more than 2 cm apart from the index ulcer.
  5. Study ulcer (i.e. current episode of ulceration) has been present for greater than one month prior to the initial screening visit, and has failed to respond to documented conservative measures for greater than (1) one month duration and is excluded if it has undergone 12 months of continuous high strength compression therapy over its duration.
  6. Study ulcer is a minimum of 2 cm2 and a maximum of 20 cm2 at the randomization visit.
  7. The target ulcer has been treated with compression therapy for at least 14 days prior to randomization.
  8. Ulcer has a clean, granulating base with minimal adherent slough at the randomization visit.
  9. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  10. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
  11. Subject has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria:

  1. Study ulcer(s) deemed by the investigator to be caused by a medical condition other than venous insufficiency.
  2. Study ulcer exhibits clinical signs and symptoms of infection.
  3. Known allergy to the components of the multi-layer compression bandaging, or who cannot tolerate multi-layer compression therapy.
  4. Study ulcer, in the opinion of the investigator, is suspicious for cancer should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
  5. Subjects with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  6. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding Screening.
  7. Study ulcer improving greater than 30% during the screening phase if the subject was not in adequate compression 14 days prior to screening.
  8. History of drug or alcohol abuse.
  9. History of radiation at the ulcer site.
  10. Presence of one or more medical conditions, as determined by medical history, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this ulcer healing study.
  11. History of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  12. Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Matristem) within the last 30 days
  13. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.
  14. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  15. Ulcers on the dorsum of the foot or with more than 50% of the ulcer below the malleolus are excluded.
  16. Pregnant or breast feeding.
  17. Presence of diabetes with poor metabolic control as documented with a HgA1c > 12.0 within last 90 days
  18. Patients with renal dysfunction whose serum creatinine levels are 3.0mg/dl or greater within the last 90 days
  19. History of usage of tobacco products within the last 30 days
  20. History of Liver disease with active Cirrhosis of the liver

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02609594

Layout table for location contacts
Contact: Heather Connell, CCRP 617-383-3979

Layout table for location information
United States, Massachusetts
Brigham and Women's Hospital Wound Care Center Recruiting
Boston, Massachusetts, United States, 02115
Contact: Laurie Bayer, PA-C    617-732-8743      
Principal Investigator: Indranil Sinha, MD         
United States, New Jersey
Premier Surgical Recruiting
Brick, New Jersey, United States, 08723
Contact: Jarrod Kaufman, MD    732-262-1600      
Inspira Medical Center - Elmer Wound Care Center Completed
Elmer, New Jersey, United States, 08318
United States, Oklahoma
St John Medical Center Completed
Tulsa, Oklahoma, United States, 74135
United States, Pennsylvania
The Foot and Ankle Wellness Center Recruiting
Ford City, Pennsylvania, United States, 16226
Contact: Matthew Sabo, DPM    724-763-4080      
Armstrong County Memorial Hospital Recruiting
Kittanning, Pennsylvania, United States, 16201
Contact: Keyur Patel, MD    724-543-8893      
SerenaGroup Research Institute Recruiting
Pittsburgh, Pennsylvania, United States, 15222
Contact: Thomas Serena, MD    814-688-4000      
United States, Virginia
Martinsville Research Institute Recruiting
Martinsville, Virginia, United States, 24112
Contact: Kim Young    540-676-5886      
Principal Investigator: Nathan Young, DPM         
Sponsors and Collaborators
SerenaGroup, Inc.
Musculoskeletal Transplant Foundation
Layout table for investigator information
Study Director: Linda Squillante Musculoskeletal Transplant Foundation

Layout table for additonal information
Responsible Party: Thomas Serena, Principal Investigator, SerenaGroup, Inc. Identifier: NCT02609594    
Other Study ID Numbers: AMNIOVLU01
First Posted: November 20, 2015    Key Record Dates
Last Update Posted: September 7, 2018
Last Verified: September 2018
Keywords provided by Thomas Serena, SerenaGroup, Inc.:
human amniotic membrane
compression therapy
venous leg ulcer
Additional relevant MeSH terms:
Layout table for MeSH terms
Varicose Ulcer
Leg Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases